ORGENESIS INC. (OTCMKTS:ORGS) Files An 8-K Results of Operations and Financial Condition

ORGENESIS INC. (OTCMKTS:ORGS) Files An 8-K Results of Operations and Financial Condition

Story continues below

(d) Exhibits.

99.1 Press Release of Orgenesis Inc. dated July 17, 2018.

Orgenesis Inc. Exhibit
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Orgenesis Inc.: Exhibit 99.1 – Filed by Orgenesis Reports 73% Increase in Revenue for the Second Quarter of Fiscal 2018 CDMO segment achieves operating profit of $1.2 million GERMANTOWN,…
To view the full exhibit click here


Orgenesis Inc. is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company’s subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: process and assay development services and good manufacturing practice (GMP) contract manufacturing services. The CTB activity is based on its technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into pancreatic beta cell-like insulin producing cells for patients with Type I Diabetes. It intends to advance a product that combines cell-based therapy and regenerative medicine, Autologous Insulin Producing (AIP) cells, into clinical development.

An ad to help with our costs